Publications 2022

Smeland K, Holte H, Fagerli UM, Bersvendsen H, Hjermstad MJ, Loge JH, Murbrach K, Linnsund MD, Fluge O, Stenehjem JS, Lund MB, Kvaloy S, Kiserud CE (2022)
Total late effect burden in long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplant and its effect on health-related quality of life
Haematologica, 107 (11), 2698-2707
DOI 10.3324/haematol.2021.280413, PubMed 35484681

Publications 2018

Åsli LM, Myklebust TÅ, Kvaløy SO, Jetne V, Møller B, Levernes SG, Johannesen TB (2018)
Factors influencing access to palliative radiotherapy: a Norwegian population-based study
Acta Oncol, 57 (9), 1250-1258
DOI 10.1080/0284186X.2018.1468087, PubMed 29706109

Publications 2017

Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaløy SO, Wethal T, Kiserud CE, Samersaw-Lund MB (2017)
Obstructive and restrictive pulmonary dysfunction in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation
Acta Oncol, 57 (6), 773-781
DOI 10.1080/0284186X.2017.1406137, PubMed 29171324

Publications 2016

Kiserud CE, Fagerli UM, Smeland KB, Fluge Ø, Bersvendsen H, Kvaløy S, Holte H, Dahl AA (2016)
Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation
Acta Oncol, 55 (5), 547-53
DOI 10.3109/0284186X.2015.1125015, PubMed 27123741

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Østenstad B, Kvaløy S, Holte H (2016)
A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma
Br J Haematol, 173 (3), 432-43
DOI 10.1111/bjh.13965, PubMed 26914167

Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaløy S, Thorsen L, Arbo I, Jones LW, Aakhus S, Lund MB, Kiserud CE (2016)
Cardiorespiratory fitness in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation
Br J Cancer, 115 (2), 178-87
DOI 10.1038/bjc.2016.180, PubMed 27351215

Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaløy S, Wethal T, Kiserud CE, Lund MB (2016)
Diffusing capacity impairment is prevalent in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation
Bone Marrow Transplant, 52 (4), 646-649
DOI 10.1038/bmt.2016.338, PubMed 27991891

Torfoss D, Fladhagen T, Holte H, Brinch L, Schjesvold FH, Fløisand Y, Nyquist E, Dalgaard J, Meyer P, Lehmann AK, Hammerstrøm J, Skjelbakken T, Høiby EA, Sandvik L, Kvaløy S (2016)
Benzylpenicillin plus an aminoglycoside versus meropenem in neutropenic lymphoma and leukaemia patients with a suspected bacterial infection: a randomized, controlled trial
Clin Microbiol Infect, 23 (3), 179-187
DOI 10.1016/j.cmi.2016.10.019, PubMed 27793737

Publications 2015

Murbraech K, Smeland KB, Holte H, Loge JH, Lund MB, Wethal T, Holte E, Rösner A, Dalen H, Kvaløy S, Falk RS, Aakhus S, Kiserud CE (2015)
Heart Failure and Asymptomatic Left Ventricular Systolic Dysfunction in Lymphoma Survivors Treated With Autologous Stem-Cell Transplantation: A National Cross-Sectional Study
J Clin Oncol, 33 (24), 2683-91
DOI 10.1200/JCO.2015.60.8125, PubMed 26169610

Smeland KB, Kiserud CE, Lauritzsen GF, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Kvaløy S, Holte H (2015)
Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway
Haematologica, 100 (6), e240-3
DOI 10.3324/haematol.2014.119214, PubMed 25682605

Publications 2014

Asli LM, Kvaløy SO, Jetne V, Myklebust TÅ, Levernes SG, Tveit KM, Green TO, Johannesen TB (2014)
Utilization of radiation therapy in Norway after the implementation of the national cancer plan--a national, population-based study
Int J Radiat Oncol Biol Phys, 90 (3), 707-14
DOI 10.1016/j.ijrobp.2014.06.059, PubMed 25160610

Publications 2013

Bersvendsen H, Kolstad A, Blystad AK, Aurlien E, Fosså A, Kvaløy SO, Holte H, Lauritzsen GF (2013)
Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma
Acta Oncol, 53 (5), 680-7
DOI 10.3109/0284186X.2013.855816, PubMed 24237392

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Fluge Ø, Fosså A, Hammerstrøm J, Kolstad A, Loge JH, Maisenhølder M, Østenstad B, Kvaløy S, Holte H (2013)
High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008
Tidsskr Nor Laegeforen, 133 (16), 1704-9
DOI 10.4045/tidsskr.13.0243, PubMed 24005706

Smeland KB, Kiserud CE, Lauritzsen GF, Fosså A, Hammerstrøm J, Jetne V, Kolstad A, Kvalheim G, Loge JH, Løkeland T, Tangen JM, Holte H, Kvaløy S (2013)
High-dose therapy with autologous stem cell support for lymphoma--from experimental to standard treatment
Tidsskr Nor Laegeforen, 133 (16), 1735-9
DOI 10.4045/tidsskr.13.0319, PubMed 24005713

Wethal T, Nedregaard B, Andersen R, Fosså A, Lund MB, Günther A, Kvaløy S, Fosså SD, Kjekshus J (2013)
Atherosclerotic lesions in lymphoma survivors treated with radiotherapy
Radiother Oncol, 110 (3), 448-54
DOI 10.1016/j.radonc.2013.10.029, PubMed 24231235

Publications 2011

Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N, MabThera International Trial (MInT) Group (2011)
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
Lancet Oncol, 12 (11), 1013-22
DOI 10.1016/S1470-2045(11)70235-2, PubMed 21940214

Torfoss D, Høiby EA, Holte H, Kvaløy S (2011)
The Norwegian experience with penicillin G plus an aminoglycoside as initial empiric therapy in febrile neutropenia; a review
Acta Oncol, 51 (4), 433-40
DOI 10.3109/0284186X.2011.633931, PubMed 22175253

Torfoss D, Sandstad B, Mollnes TE, Høiby EA, Holte H, Bjerner J, Bjøro T, Gaudernack G, Kvalheim G, Kvaløy S (2011)
The mild inflammatory response in febrile neutropenic lymphoma patients with low risk of complications is more pronounced in patients receiving tobramycin once daily compared with three times daily
Scand J Immunol, 74 (6), 632-9
DOI 10.1111/j.1365-3083.2011.02618.x, PubMed 21883353

Publications 2010

Johnsen HE, Geisler C, Juvonen E, Remes K, Juliusson G, Hörnsten P, Kvaloy S, Kvalheim G, Jürgensen GW, Pedersen LM, Bergmann OJ, Schmitz A, Boegsted M (2010)
Priming with r-metHuSCF and filgrastim or chemotherapy and filgrastim in patients with malignant lymphomas: a randomized phase II pilot study of mobilization and engraftment
Bone Marrow Transplant, 46 (1), 44-51
DOI 10.1038/bmt.2010.84, PubMed 20436517

Ruland CM, Holte HH, Røislien J, Heaven C, Hamilton GA, Kristiansen J, Sandbaek H, Kvaløy SO, Hasund L, Ellison MC (2010)
Effects of a computer-supported interactive tailored patient assessment tool on patient care, symptom distress, and patients' need for symptom management support: a randomized clinical trial
J Am Med Inform Assoc, 17 (4), 403-10
DOI 10.1136/jamia.2010.005660, PubMed 20595307

Zaikova O, Fosså SD, Kongsgaard U, Kvaløy S, Giercksky KE, Skjeldal S (2010)
Pain after palliative radiotherapy for spine metastases
Clin Oncol (R Coll Radiol), 22 (10), 828-36
DOI 10.1016/j.clon.2010.03.008, PubMed 20363110

Publications 2009

Dahl O, Kvaløy S, Lehne G, Baksaas I, Christoffersen T (2009)
Medikamentell kreftbehandling
In Cytostatikaboken 7. utgave 2009 (Dahl O, Lehne G, Baksaas I, Kvaløy S, Christoffersen T, eds.), Farmakologisk Institutt, Universitetet i Oslo, Oslo, Norge
PublikaID 77, ISBN 9788299233125

Dahl O, Kvaløy SO, Lehne G, Baksaas I, Christoffersen T (2009)
Medikamentell kreftbehandling
In Cytostatikaboken. 7. utgave (Dahl O, Kvaløy SO, Lehne G, Baksaas I, Christoffersen T, eds.), Farmakologisk institutt, Universitetet i Oslo, Oslo
PublikaID 88

Holte H, Kvaløy S, Delabie J, Trøen G, Smeland EB (2009)
[Molecular diagnosis of malignant lymphomas]
Tidsskr Nor Laegeforen, 129 (22), 2352-6
DOI 10.4045/tidsskr.09.0704, PubMed 19935935

Jetne V, Kvaløy S, Smeland S, Johannesen TB, Tveit KM (2009)
[Use of radiotherapy in South-Eastern Norway Regional Health Authority]
Tidsskr Nor Laegeforen, 129 (24), 2602-5
DOI 10.4045/tidsskr.09.0331, PubMed 20029555

Zaikova O, Giercksky KE, Fosså SD, Kvaløy S, Johannesen TB, Skjeldal S (2009)
A population-based study of spinal metastatic disease in South-East Norway
Clin Oncol (R Coll Radiol), 21 (10), 753-9
DOI 10.1016/j.clon.2009.09.023, PubMed 19850454

Publications 2008

Fosså SD, Kvaløy J, Kvaløy S, Loge JH, Dahl AA (2008)
[Courses for cancer patients--15 years' experience at The Montebello Centre in Norway]
Tidsskr Nor Laegeforen, 128 (22), 2554-7
PubMed 19023349

Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G et al. (2008)
Stromal gene signatures in large-B-cell lymphomas
N Engl J Med, 359 (22), 2313-23
DOI 10.1056/NEJMoa0802885, PubMed 19038878

Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Zinzani PL, Mingrone W, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Corrado C, Scheliga A, Loeffler M, Kuhnt E, MabThera International Trial (MInT) Group (2008)
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study
Lancet Oncol, 9 (5), 435-44
DOI 10.1016/S1470-2045(08)70078-0, PubMed 18400558

Torfoss D, Høiby EA, Holte H, Kvaløy S (2008)
[Penicillin and aminoglycoside in febrile neutropenia]
Tidsskr Nor Laegeforen, 128 (23), 2738-40
PubMed 19079423

Publications 2007

Björkholm M, Hagberg H, Holte H, Kvaloy S, Teerenhovi L, Anderson H, Cavallin-Ståhl E, Myhre J, Pertovaara H, Ost A, Nilsson B, Osby E (2007)
Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up
Ann Oncol, 18 (6), 1085-9
DOI 10.1093/annonc/mdm073, PubMed 17363838

Torfoss D, Høiby EA, Tangen JM, Holte H, Bø K, Meyer P, Grøttum K, Weyde K, Lauritzsen GF, Sandstad B, Jacobsen AB, Olsen H, Kvaløy S (2007)
Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial
J Antimicrob Chemother, 59 (4), 711-7
DOI 10.1093/jac/dkm003, PubMed 17327294

Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, Nakayama K, Liu H, Rosenwald A, Muller-Hermelink HK, Ott G, Chan WC, Greiner TC, Weisenburger DD, Vose J, Armitage JO, Gascoyne RD, Connors JM, Campo E, Montserrat E, Bosch F, Smeland EB, Kvaloy S, Holte H, Delabie J, Fisher RI et al. (2007)
Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival
Blood, 109 (11), 4599-606
DOI 10.1182/blood-2006-08-039859, PubMed 17299095

Publications 2006

Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB et al. (2006)
Molecular diagnosis of Burkitt's lymphoma
N Engl J Med, 354 (23), 2431-42
DOI 10.1056/NEJMoa055759, PubMed 16760443

Hjermstad MJ, Hollender A, Warloe T, Karlsen KO, Ikonomo I, Kvaloy S, Nome O, Holte H (2006)
Quality of life after total or partial gastrectomy for primary gastric lymphoma
Acta Oncol, 45 (2), 202-9
DOI 10.1080/02841860500492067, PubMed 16546867

Hollender A, Bjøro T, Otto Karlsen K, Kvaloy SO, Nome O, Holte H (2006)
Vitamin D deficiency in patients operated on for gastric lymphoma
Scand J Gastroenterol, 41 (6), 673-81
DOI 10.1080/00365520500356510, PubMed 16716965

Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial Group (2006)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
Lancet Oncol, 7 (5), 379-91
DOI 10.1016/S1470-2045(06)70664-7, PubMed 16648042

Publications 2005

Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R et al. (2005)
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction
Blood, 106 (9), 3183-90
DOI 10.1182/blood-2005-04-1399, PubMed 16046532

Fosså SD, Holte H, Holmen MM, Bjøro T, Langmark F, Hess SL, Kvaløy S (2005)
[Long-term effects after mantle field radiotherapy for Hodgkin's lymphoma]
Tidsskr Nor Laegeforen, 125 (1), 41-4
PubMed 15643464

Mishra V, Andresen S, Brinch L, Kvaløy S, Ernst P, Lønset MK, Tangen JM, Wikelund J, Flatum C, Baggerød E, Helle B, Vaaler S, Hagen TP (2005)
Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study
Bone Marrow Transplant, 35 (12), 1149-53
DOI 10.1038/sj.bmt.1704988, PubMed 15880133

Torlakovic E, Malecka A, Myklebust JH, Tierens A, Aasheim HC, Nesland JM, Smeland E, Kvaløy S, Delabie J (2005)
PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor
J Pathol, 206 (3), 312-9
DOI 10.1002/path.1777, PubMed 15892171

Publications 2004

Blystad AK, Delabie J, Kvaløy S, Holte H, Vålerhaugen H, Ikonomou I, Kvalheim G (2004)
Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy
Br J Haematol, 125 (5), 605-12
DOI 10.1111/j.1365-2141.2004.04951.x, PubMed 15147376

Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA et al. (2004)
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
N Engl J Med, 351 (21), 2159-69
DOI 10.1056/NEJMoa041869, PubMed 15548776

Jerkeman M, Anderson H, Dictor M, Kvaløy S, Akerman M, Cavallin-Ståhl E, Nordic Lymphoma Group study (2004)
Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study
Ann Hematol, 83 (7), 414-9
DOI 10.1007/s00277-004-0855-x, PubMed 15085385

Jerkeman M, Leppä S, Kvaløy S, Holte H (2004)
ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience
Eur J Haematol, 73 (3), 179-82
DOI 10.1111/j.1600-0609.2004.00294.x, PubMed 15287915

Smeland S, Blystad AK, Kvaløy SO, Ikonomou IM, Delabie J, Kvalheim G, Hammerstrøm J, Lauritzsen GF, Holte H (2004)
Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens
Ann Oncol, 15 (7), 1072-8
DOI 10.1093/annonc/mdh262, PubMed 15205201

Publications 2003

Hjermstad MJ, Evensen SA, Kvaløy SO, Loge JH, Fayers PM, Kaasa S (2003)
The CARES-SF used for prospective assessment of health-related quality of life after stem cell transplantation
Psychooncology, 12 (8), 803-13
DOI 10.1002/pon.708, PubMed 14681953

Kvaløy S (2003)
[Norwegian program for malignant lymphomas]
Tidsskr Nor Laegeforen, 123 (7), 914
PubMed 12737057

Linderoth J, Jerkeman M, Cavallin-Ståhl E, Kvaløy S, Torlakovic E, Nordic Lymphoma Group Study (2003)
Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study
Clin Cancer Res, 9 (2), 722-8
PubMed 12576441

Osby E, Hagberg H, Kvaløy S, Teerenhovi L, Anderson H, Cavallin-Stahl E, Holte H, Myhre J, Pertovaara H, Björkholm M, Nordic Lymphoma Group (2003)
CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial
Blood, 101 (10), 3840-8
DOI 10.1182/blood-2002-10-3238, PubMed 12531794

Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R et al. (2003)
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
J Exp Med, 198 (6), 851-62
DOI 10.1084/jem.20031074, PubMed 12975453

Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC et al. (2003)
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
Cancer Cell, 3 (2), 185-97
DOI 10.1016/s1535-6108(03)00028-x, PubMed 12620412

Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE, Doorduijn JK, Sydes MR, Kvalheim G (2003)
High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial
J Clin Oncol, 21 (21), 3918-27
DOI 10.1200/JCO.2003.10.023, PubMed 14517188

Publications 2002

Foss Abrahamsen A, Andersen A, Nome O, Jacobsen AB, Holte H, Foss Abrahamsen J, Kvaløy S (2002)
Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time
Ann Oncol, 13 (11), 1786-91
DOI 10.1093/annonc/mdf289, PubMed 12419752

Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H (2002)
Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model
Ann Oncol, 13 (7), 1099-107
DOI 10.1093/annonc/mdf175, PubMed 12176790

Holte H, Smeland S, Blystad AK, Kvaløy S, Hammerstrøm J, Tjønnfjord GE (2002)
[Intensive chemotherapy in Burkitt's lymphoma and aggressive non-Hodgkin's lymphoma]
Tidsskr Nor Laegeforen, 122 (4), 364-9
PubMed 11915663

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ et al. (2002)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
N Engl J Med, 346 (25), 1937-47
DOI 10.1056/NEJMoa012914, PubMed 12075054

Publications 2001

Aurlien E, Holte H, Kvaloy S, Jakobsen E, Rusten LS, Kvalheim G (2001)
Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients
Eur. J. Haematol., 66 64, 14-20

Aurlien E, Holte H, Kvaløy S, Jakobsen E, Rusten LS, Kvalheim G (2001)
Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients
Eur J Haematol Suppl, 64, 14-20
PubMed 11486395

Blystad AK, Enblad G, Kvaløy S, Berglund A, Delabie J, Holte H, Carlson K, Kvalheim G, Bengtsson M, Hagberg H (2001)
High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas
Bone Marrow Transplant, 27 (7), 711-6
DOI 10.1038/sj.bmt.1702867, PubMed 11360110

Blystad AK, Holte H, Kvaløy S, Smeland E, Delabie J, Kvalheim G (2001)
High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells
Bone Marrow Transplant, 28 (9), 849-57
DOI 10.1038/sj.bmt.1703244, PubMed 11781645

Blystad AK, Torlakovic E, Holte H, Kvaløy S, Lenschow E, Kvalheim G (2001)
CD34(+) cell enrichment depletes atypical CD30(+) cells from PBPC grafts in patients with HD
Cytotherapy, 3 (4), 295-305
DOI 10.1080/146532401317070934, PubMed 12171718

Jerkeman M, Kaasa S, Hjermstad M, Kvaløy S, Cavallin-Stahl E (2001)
Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial
Med Oncol, 18 (1), 85-94
DOI 10.1385/MO:18:1:85, PubMed 11778974

Kvaløy S, Mathiassen M (2001)
Kostråd til kreftpasienter: informasjon til pasienter, pårørende og andre interesserte
In Kreftinfo, Den norske kreftforening, Oslo, 6/2001 (6. oppl.), 48 s.
BIBSYS 022497749

Nordøy T, Husebekk A, Aaberge IS, Jenum PA, Samdal HH, Flugsrud LB, Kristoffersen AC, Holte H, Kvaløy S, Kolstad A (2001)
Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines
Bone Marrow Transplant, 28 (7), 681-7
DOI 10.1038/sj.bmt.1703228, PubMed 11704791

Sweetenham JW, Santini G, Qian W, Guelfi M, Schmitz N, Simnett S, Nagler A, Holte H, Kvaloy S, Bruzzi P, Goldstone AH (2001)
High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group
J Clin Oncol, 19 (11), 2927-36
DOI 10.1200/JCO.2001.19.11.2927, PubMed 11387366

Tanum G, Olsen DR, Grøttum K, Mjåland S, Kvaløy S, Jetne V, Kvinnsland S (2001)
[The radiotherapy satellite in Kristiansand--a model for Norwegian regional hospitals?]
Tidsskr Nor Laegeforen, 121 (18), 2179-82
PubMed 11571996

Publications 2000

Hollender A, Kvaloy S, Lote K, Nome O, Holte H (2000)
Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis
Eur J Cancer, 36 (14), 1762-8
DOI 10.1016/s0959-8049(00)00171-4, PubMed 10974623

Knobel H, Loge JH, Nordøy T, Kolstad AL, Espevik T, Kvaløy S, Kaasa S (2000)
High level of fatigue in lymphoma patients treated with high dose therapy
J Pain Symptom Manage, 19 (6), 446-56
DOI 10.1016/s0885-3924(00)00144-5, PubMed 10908825

Lote K, Holte H, Kvaloy S (2000)
Testicular lymphoma is associated with a high risk of extranodal recurrence
Cancer, 89 (3), 713-4
PubMed 10931479

Lote K, Holte H, Nome O, Langholm R, Kvaløy S (2000)
Stage I high-grade non-Hodgkin's lymphoma
Acta Oncol, 39 (7), 865-72
DOI 10.1080/028418600750063631, PubMed 11145446

Schouten HC, Kvaloy S, Sydes M, Qian W, Fayers PM (2000)
The CUP trial: a randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL)
Ann Oncol, 11 Suppl 1, 91-4
PubMed 10707787

Publications 1999

Abrahamsen AF, Loge JH, Hannisdal E, Nome O, Lund MB, Holte H, Kvaløy S (1999)
Late medical sequelae after therapy for supradiaphragmatic Hodgkin's disease
Acta Oncol, 38 (4), 511-5
DOI 10.1080/028418699432068, PubMed 10418720

Blystad A, Kvalheim G, Torlakovic E, Holte H, Jacobsen E, Beiske K, Vâlerhaugen H, Lenschow E, Kvaloy S (1999)
High-dose therapy supported with immunomagnetic purged autologous bone marrow in high-grade B cell non-Hodgkin's lymphoma
Bone Marrow Transplant, 24 (8), 865-72
DOI 10.1038/sj.bmt.1701990, PubMed 10516698

Hjermstad MJ, Evensen SA, Kvaløy SO, Fayers PM, Kaasa S (1999)
Health-related quality of life 1 year after allogeneic or autologous stem-cell transplantation: a prospective study
J Clin Oncol, 17 (2), 706-18
DOI 10.1200/JCO.1999.17.2.706, PubMed 10080617

Hjermstad MJ, Loge JH, Evensen SA, Kvaløy SO, Fayers PM, Kaasa S (1999)
The course of anxiety and depression during the first year after allogeneic or autologous stem cell transplantation
Bone Marrow Transplant, 24 (11), 1219-28
DOI 10.1038/sj.bmt.1702046, PubMed 10642812

Holte H, Suo Z, Smeland EB, Kvaløy S, Langholm R, Stokke T (1999)
Prognostic value of lymphoma-specific S-phase fraction compared with that of other cell proliferation markers
Acta Oncol, 38 (4), 495-503
DOI 10.1080/028418699432040, PubMed 10418718

Jerkeman M, Anderson H, Cavallin-Ståhl E, Dictor M, Hagberg H, Johnson A, Kaasa S, Kvaløy S, Sundström C, Akerman M (1999)
CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial
Ann Oncol, 10 (9), 1079-86
DOI 10.1023/a:1008392528248, PubMed 10572606

Nordøy T, Kolstad A, Endresen P, Holte H, Kvaløy S, Kvalheim G, Husebekk A (1999)
Persistent changes in the immune system 4-10 years after ABMT
Bone Marrow Transplant, 24 (8), 873-8
DOI 10.1038/sj.bmt.1702006, PubMed 10516699

Publications 1998

Abrahamsen AF, Loge JH, Hannisdal E, Holte H, Kvaløy S (1998)
Socio-medical situation for long-term survivors of Hodgkin's disease: a survey of 459 patients treated at one institution
Eur J Cancer, 34 (12), 1865-70
DOI 10.1016/s0959-8049(98)00269-x, PubMed 10023307

Aurlien E, Holte H, Pharo A, Kvaløy S, Jakobsen E, Smeland EB, Kvalheim G (1998)
Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma
Bone Marrow Transplant, 21 (9), 873-8
DOI 10.1038/sj.bmt.1701192, PubMed 9613778

Galteland E, Sivertsen EA, Lote K, Holte H, Kvaløy S (1998)
[Primary non-Hodgkin's lymphoma of the brain]
Tidsskr Nor Laegeforen, 118 (29), 4524-6
PubMed 9889638

Ose T, Blaker B, Kvaløy S, Kolset T, Fluge G (1998)
[The importance of nutrition for cancer patients]
Tidsskr Nor Laegeforen, 118 (22), 3466-70
PubMed 9800498

Stokke T, Smeland EB, Kvaløy S, Holte H (1998)
Tumour cell proliferation, but not apoptosis, predicts survival in B-cell non-Hodgkin's lymphomas
Br J Cancer, 77 (11), 1839-41
DOI 10.1038/bjc.1998.305, PubMed 9667655

Publications 1997

Foss Abrahamsen A, Egeland T, Hansen S, Langholm R, Holte H, Kvaløy S (1997)
Hodgkin's disease in a national and hospital population: trends over 20 years
Eur J Cancer, 33 (14), 2380-3
DOI 10.1016/s0959-8049(97)00342-0, PubMed 9616285

Gundersen S, Kvaløy S, Hannisdal E (1997)
[Check up of breast cancer stages 1 and 2]
Tidsskr Nor Laegeforen, 117 (8), 1079-81
PubMed 9148472

Lien HH, Blomlie V, Blystad AK, Holte H, Langholm R, Kvaløy S (1997)
Bone-marrow MR imaging before and after autologous marrow transplantation in lymphoma patients without known bone-marrow involvement
Acta Radiol, 38 (5), 896-902
DOI 10.1080/02841859709172432, PubMed 9332252

Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, Pinkerton CR, Schey SA, Jacobs F, Oakhill A, Stevens RF, Darbyshire PJ, Gibson BE (1997)
A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients
Br J Haematol, 98 (3), 711-8
DOI 10.1046/j.1365-2141.1997.2473063.x, PubMed 9332329

Publications 1996

Abrahamsen AF, Hannisdal E, Nome O, Elgio RF, Holte H, Hager B, Langholm R, Kvaløy S (1996)
Prognostic variables and results of salvage treatment in Hodgkin's disease
Acta Oncol, 35 Suppl 8, 67-72
DOI 10.3109/02841869609098522, PubMed 9073050

Abrahamsen AF, Hannisdal E, Nome O, Holte H, Hager B, Langholm R, Kvaløy S (1996)
Clinical stage I and II Hodgkin's disease: long-term results of therapy without laparotomy. Experience at one institution
Ann Oncol, 7 (2), 145-50
DOI 10.1093/oxfordjournals.annonc.a010541, PubMed 8777170

Holte H, Kvaløy SO, Engan T, Evensen SA, Mella O, Tangen JM, Wesenberg F, Wist EA (1996)
[High dose therapy with autologous stem cell support in malignant disorders. Excerpt from the statement by the advisory group of the State Health Services]
Tidsskr Nor Laegeforen, 116 (21), 2577-81
PubMed 8928130

Kolstad A, Holte H, Kvaløy S, Jakobsen E, Erikstein B, Aurlien E, Kvalheim G, Bøhler PJ, Langholm R (1996)
[High-dose therapy with autologous stem cell support in malignant lymphoma and breast cancer. Experiences with hematopoietic stem cells isolate from blood]
Tidsskr Nor Laegeforen, 116 (21), 2547-51
PubMed 8928122

Kvalheim G, Holte H, Jakobsen E, Kvaloy S (1996)
Immunomagnetic purging of lymphoma cells from autografts
J Hematother, 5 (5), 561-2
DOI 10.1089/scd.1.1996.5.561, PubMed 8938530

Kvalheim G, Pharo A, Holte H, Jakobsen E, Erikstein B, Kvaløy S, Beiske K, Nesland JM, Smeland EB (1996)
[High-dose therapy of cancer with CD34 positive cells as stem cell support]
Tidsskr Nor Laegeforen, 116 (21), 2542-6
PubMed 8928121

Kvalheim G, Wang MY, Pharo A, Holte H, Jacobsen E, Beiske K, Kvaløy S, Smeland E, Funderud S, Fodstad O (1996)
Purging of tumor cells from leukapheresis products: experimental and clinical aspects
J Hematother, 5 (4), 427-36
DOI 10.1089/scd.1.1996.5.427, PubMed 8877718

Sletnes KE, Holte H, Halvorsen S, Jakobsen E, Wisløff F, Kvaløy S (1996)
Activation of coagulation and deep vein thrombosis after bone marrow harvesting and insertion of a Hickman-catheter in ABMT patients with malignant lymphoma
Bone Marrow Transplant, 17 (4), 577-81
PubMed 8722358

Publications 1995

Kvaløy S (1995)
[Quality assurance in health care--a paper tiger?]
Tidsskr Nor Laegeforen, 115 (26), 3235-6
PubMed 7482449

Kvaløy S (1995)
Høydosebehandling med autolog stamcellestøtte ved malignelidelser: innstilling
In Utredningsserie, Tilsynet, Oslo, 1-95, 85 s.
BIBSYS 952074257

AAS M, LIEN HH, NOME O, WINDEREN M, HAGER B, KVALOY S, ABRAHAMSEN AF (1995)
GA-67 SCINTIGRAPHY, MRI AND CT IN THE FOLLOW-UP OF MALIGNANT-LYMPHOMA PATIENTS WITH RESIDUAL MEDIASTINAL MASS
ADV PHAR SC, 51-56

Publications 1994

Abrahamsen AF, Lien HH, Aas M, Winderen M, Hager B, Kvaløy S, Elgjo RF, Nome O (1994)
Magnetic resonance imaging and 67gallium scan in mediastinal malignant lymphoma: a prospective pilot study
Ann Oncol, 5 (5), 433-6
DOI 10.1093/oxfordjournals.annonc.a058875, PubMed 8075050

Kvaløy SO, Smeland EB (1994)
[Bone marrow transplantation--a constantly developing procedure--requiring updating]
Tidsskr Nor Laegeforen, 114 (3), 302-3
PubMed 8191422

Publications 1993

Abrahamsen AF, Hannisdal E, Abrahamsen JF, Nome O, Høst H, Kvaløy SO (1993)
[Hodgkin's disease or lymphogranulomatosis. New views on prognosis, complicating conditions and complications after treatment]
Tidsskr Nor Laegeforen, 113 (23), 2899-903
PubMed 8236190

Abrahamsen JF, Andersen A, Hannisdal E, Nome O, Abrahamsen AF, Kvaløy S, Høst H (1993)
Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age
J Clin Oncol, 11 (2), 255-61
DOI 10.1200/JCO.1993.11.2.255, PubMed 8426202

Abrahamsen JF, Andersen A, Hannisdal E, Nome O, Kvaløy SO, Høst H, Abrahamsen AF (1993)
[New cancer disease after treatment of Hodgkin's disease]
Tidsskr Nor Laegeforen, 113 (23), 2903-5
PubMed 8236191

Erikstein BK, Holte H, Kvaløy S, Andersson KB, Steen HB, Hannisdal E, Smeland EB (1993)
Expression of CD18 (integrin beta 2 chain) correlates with prognosis in malignant B cell lymphomas
Br J Haematol, 83 (3), 392-8
DOI 10.1111/j.1365-2141.1993.tb04662.x, PubMed 8097923

Hannisdal E, Gundersen S, Kvaløy S, Lindegaard MW, Aas M, Finnanger AM, Jørgensen OG, Theodorsen L, Høst H (1993)
Follow-up of breast cancer patients stage I-II: a baseline strategy
Eur J Cancer, 29A (7), 992-7
DOI 10.1016/s0959-8049(05)80208-4, PubMed 8098950

Publications 1992

Abrahamsen AF, Jakobsen E, Langholm R, Abrahamsen JF, Kvaløy S, Nome O (1992)
Bone marrow examination in Hodgkin's disease
Acta Oncol, 31 (1), 41-2
DOI 10.3109/02841869209088263, PubMed 1586503

Rusten L, Kvaløy SO, Jakobsen E, Kvalheim G, Abrahamsen AF, Høiby EA, Sandven P, Lassen J, Bruu AL (1992)
[Infection problems in the leukopenia phase after autologous bone marrow transplantation]
Tidsskr Nor Laegeforen, 112 (13), 1723-6
PubMed 1509434

Wang MY, Kvalheim G, Kvaløy S, Beiske K, Jakobsen E, Wijdenes J, Pihl A, Fodstad O (1992)
An effective immunomagnetic method for bone marrow purging in T cell malignancies
Bone Marrow Transplant, 9 (5), 319-23
PubMed 1617315

Publications 1991

Nome O, Kvaløy S, Abrahamsen AF, Giercksky KE, Langholm R (1991)
[Non-Hodgkin's lymphoma in the gastrointestinal tract]
Tidsskr Nor Laegeforen, 111 (1), 59-60
PubMed 2000590

Wibe E, Kvaløy S, Nome O, Abrahamsen AF, Bjørgo S (1991)
[Tumor lysis syndrome. A life-threatening complication during cytostatic treatment of chemosensitive types of cancer]
Tidsskr Nor Laegeforen, 111 (19), 2435-7
PubMed 1926084

Publications 1990

BRINCH L, HANNISDAL E, ABRAHAMSEN AF, KVALOY S, LANGHOLM R (1990)
EXTRAMEDULLARY PLASMACYTOMAS AND SOLITARY PLASMA-CELL TUMORS OF BONE
Eur. J. Haematol., 44 (2), 131-134

Brinch L, Hannisdal E, Abrahamsen AF, Kvaløy S, Langholm R (1990)
Extramedullary plasmacytomas and solitary plasma cell tumours of bone
Eur J Haematol, 44 (2), 132-5
DOI 10.1111/j.1600-0609.1990.tb00364.x, PubMed 2318296

Brinch L, Hannisdal E, Abrahamsen AF, Kvaløy S, Langholm R (1990)
[Diagnosis and treatment of solitary plasmacytoma]
Tidsskr Nor Laegeforen, 110 (12), 1515-6
PubMed 2339400

Kaasa S, Kvaløy S, Dicato MA, Ries F, Huys JV, Royer E, Carruthers L (1990)
A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group
Eur J Cancer, 26 (3), 311-4
DOI 10.1016/0277-5379(90)90227-k, PubMed 2141487

Publications 1989

Gravdahl HK, Beiske K, Langholm R, Kvaløy S, Marton PF (1989)
[Giant cell anaplastic anemia]
Tidsskr Nor Laegeforen, 109 (23), 2289-94
PubMed 2772896

Holte H, de Lange Davies C, Beiske K, Stokke T, Marton PF, Smeland EB, Høie J, Kvaløy S (1989)
Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma
Int J Cancer, 44 (6), 975-80
DOI 10.1002/ijc.2910440605, PubMed 2606582

Publications 1988

Kvalheim G, Funderud S, Kvaløy S, Gaudernack G, Beiske K, Jakobsen E, Jacobsen AB, Pihl A, Fodstad O (1988)
Successful clinical use of an anti-HLA-DR monoclonal antibody for autologous bone marrow transplantation
J Natl Cancer Inst, 80 (16), 1322-5
DOI 10.1093/jnci/80.16.1322, PubMed 3050139

Publications 1987

Holte H, Davies CD, Kvaløy S, Smeland EB, Foss-Abrahamsen A, Kaalhus O, Marton PF, Godal T (1987)
The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomas
Int J Cancer, 39 (5), 590-4
DOI 10.1002/ijc.2910390508, PubMed 3106247

Publications 1986

Gundersen S, Kvinnsland S, Klepp O, Kvaløy S, Lund E, Høst H (1986)
Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial
Eur J Cancer Clin Oncol, 22 (12), 1431-4
DOI 10.1016/0277-5379(86)90075-1, PubMed 3595668

Publications 1985

KVALOY S, MARTON PF, KAALHUS O, HOIE J, FOSSABRAHAMSEN A, GODAL T (1985)
THYMIDINE-H-3 UPTAKE IN B-CELL LYMPHOMAS - RELATIONSHIP TO TREATMENT RESPONSE AND SURVIVAL
SCAND J HAEMATOL, 34 (5), 429-435

Kvaløy S (1985)
Phenotypic and functional properties of B cell neoplasms with reference to clinical characteristics
Norwegian Cancer Society, Oslo, 1 b. (flere pag.)
BIBSYS 861035615, ISBN 82-90187-15-7

Kvaløy S, Langholm R, Kaalhus O, Marton PF, Høst H, Godal T (1985)
Immunologic subsets in B cell lymphomas defined by surface immunoglobulin isotype and complement receptor--their relationship to survival
Scand J Haematol, 35 (2), 137-44
DOI 10.1111/j.1600-0609.1985.tb01562.x, PubMed 3876595

Kvaløy S, Marton PF, Kaalhus O, Høie J, Foss-Abrahamsen A, Godal T (1985)
3H-thymidine uptake in B cell lymphomas--relationship to treatment response and survival
Scand J Haematol, 34 (5), 429-35
DOI 10.1111/j.1600-0609.1985.tb00773.x, PubMed 3925545

Melsom H, Kvaløy S, Beiske K, Funderud S, Marton PF, Godal T, Lie SO (1985)
[Monoclonal antibodies. A new tool in the diagnosis of leukemia and lymphoma]
Tidsskr Nor Laegeforen, 105 (22), 1379-82
PubMed 4049331

Publications 1984

Kvaløy S, Langholm R, Kaalhus O, Michaelsen T, Funderud S, Foss Abrahamsen A, Godal T (1984)
Transferrin receptor and B-lymphoblast antigen--their relationship to DNA synthesis, histology and survival in B-cell lymphomas
Int J Cancer, 33 (2), 173-7
DOI 10.1002/ijc.2910330204, PubMed 6319299

Onsrud M, Kvaløy S (1984)
Influence of progestogen therapy on T lymphocyte subsets
Acta Pathol Microbiol Immunol Scand C, 92 (1), 89-91
DOI 10.1111/j.1699-0463.1984.tb00057.x, PubMed 6608858

Stensvold K, Brandtzaeg P, Kvaløy S, Seip M, Lie SO (1984)
Immunoblastic lymphadenopathy with early onset in two boys: immunohistochemical study and indication of decreased proportion of circulating T-helper cells
Br J Haematol, 56 (3), 417-30
DOI 10.1111/j.1365-2141.1984.tb03972.x, PubMed 6230099

Publications 1983

Gundersen S, Kvaløy S, Fosså SD, Høst H (1983)
[Ovarian irridation and prednisone versus tamoxifen (Nolvadex) in advanced breast cancer]
Tidsskr Nor Laegeforen, 103 (27), 1873-5
PubMed 6359581

KVALOY S, ABRAHAMSEN AF, LANDAAS TO, LANGHOLM R, MARTON PF (1983)
SOLITARY PLASMACYTOMAS OF BONE
SCAND J HAEMATOL, 30 39, 23-29

Kvaløy S, Lindmo T, Davies C, Wisløff F, Godal T (1983)
Sézary cells with an unusual phenotype, their modulation with 12-O-tetradecanoyl phorbol-13-acetate (TPA) in vitro, and their relationship to T-cell development
J Clin Immunol, 3 (3), 212-21
DOI 10.1007/BF00915345, PubMed 6604064

Publications 1982

Kvaløy S, Marton PF, Høst H, Solheim BG, Godal T (1982)
Distribution of T-cell subsets identified by monoclonal antibodies in cell suspensions from lymph node biopsies of human B-cell lymphomas
Scand J Haematol, 28 (4), 293-305
DOI 10.1111/j.1600-0609.1982.tb00530.x, PubMed 6981200

Wells A, Godal T, Kvaløy S, Steen HB, Klein G (1982)
Quantitative comparison of Epstein-Barr virus receptor expression on sIgM and sIgG cell lines and B-cell lymphoma biopsies
Differentiation, 22 (2), 113-9
DOI 10.1111/j.1432-0436.1982.tb01234.x, PubMed 6290303

Publications 1981

Kvaløy S, Godal T, Marton PF, Steen H, Brenhovd IO, Abrahamsen AF (1981)
Spontaneous (H)-thymidine uptake in histological subgroups of human B-cell lymphomas
Scand J Haematol, 26 (3), 221-34
DOI 10.1111/j.1600-0609.1981.tb01650.x, PubMed 7015478

Landaas TO, Godal T, Marton PF, Kvaløy S, Langholm R, Lindmo T, Jørgensen OG, Høst H (1981)
Cell-associated immunoglobulin in human non-Hodgkin lymphomas. A comparative study of surface immunoglobulin on cells in suspension and cytoplasmic immunoglobulin by immunohistochemistry
Acta Pathol Microbiol Scand A, 89 (2), 91-101
PubMed 7023187

Publications 1980

Godal T, Kvaløy S, Heier HE (1980)
[Antibody synthesis biology. A theme with variations--from amino acid sequence and regulatory cell circuits to malignant lymphomas]
Tidsskr Nor Laegeforen, 100 (19-21), 1214-8
PubMed 6968461

KVALOY S (1980)
MAN, NATURE AND MECHANISTIC SYSTEMS - AN EXERCISE IN ECOPHILOSOPHY
ALTERNATIVE FUTURES, 3 (3), 32-46

Publications 1979

Sanner T, Brennhovd I, Christensen I, Jørgensen O, Kvaløy S (1979)
Cellular antitumor immune response in women with risk factors for breast cancer
Cancer Res, 39 (2 Pt 2), 654-7
PubMed 761231

Publications 1978

Klepp O, Kvaløy S (1978)
[Tissue necrosis caused by careless injection of cytostatic agents]
Tidsskr Nor Laegeforen, 98 (27), 1330-1
PubMed 694872